Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10173082 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL30471287 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL28510322 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL29401691 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL29398585 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL25359262 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL31144370 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL26008676 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL25359258 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL5061301 | 0.92 | KMT2A (0.58) | KMT2ACASP3MDM4TP53CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-118119623-A | Targeted protease degradation (TED) platform | 嘉兴优博生物技术有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117924411-A | Method for thioimidization of amino acid or polypeptide carboxyl locus and application of method in preparation of antitumor polypeptide coupling medicine | 兰州大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11149067-B2 | Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors | Universität Duisburg-Essen (DE) | 2021-10-19 | — | — | US | disclosed |
| CN-112979762-B | Cyclic peptide PIZ and use thereof | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2021-07-27 | — | — | CN | disclosed |
| CN-112979762-A | Cyclic peptide PIZ and use thereof | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2021-06-18 | — | — | CN | disclosed |
| US-20200071360-A1 | TAILORED CYCLODEPSIPEPTIDES AS POTENT NON-COVALENT SERINE PROTEASE INHIBITORS | Universität Duisburg-Essen (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2019243825-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING, CONJUGATES AND THERAPEUTIC APPLICATIONS | CURADEV PHARMA LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-20130252904-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | ENDOCYTE, INC. (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252904-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | FOLR1, FOLR2, DHFR | KMT2A 237/4885CASP3 521/4885PTPN1 4577/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 2979/4885CASP3 4173/4885PTPN1 4445/4885 |
| US-20200071360-A1 | TAILORED CYCLODEPSIPEPTIDES AS POTENT NON-COVALENT SERINE PROTEASE INHIBITORS | HTRA1, LNPEP, ENPEP | KMT2A 2268/4885CASP3 547/4885PTPN1 672/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 3083/4885CASP3 2783/4885PTPN1 4361/4885 |
| US-11149067-B2 | Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors | HTRA1, LNPEP, ENPEP | KMT2A 2268/4885CASP3 547/4885PTPN1 672/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | KMT2A 3415/4885CASP3 4451/4885PTPN1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.